Nath Bio-Genes board approves unaudited standalone and consolidated financial results for Q2FY27
BSE India
Nath Bio-Genes board approves the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The filing includes the statement of results and the limited review reports from the statutory auditors. No specific financial figures or segmental performance drivers are provided in this regulatory announcement.
| Sep 2026 | Jun 2026 | Sep 2025 | QoQ% | YoY% | |
|---|---|---|---|---|---|
| Revenue/Sales | 40.74 | 328.40 | 43.85 | -87.59% | -7.08% |
| EBITDA | 8.29 | 38.25 | 10.10 | -78.33% | -17.93% |
| Op. profit margin(%) | 11.38 | 10.70 | 13.92 | 6.29% | -18.27% |
| Net Profit | 0.42 | 32.26 | 2.75 | -98.70% | -84.79% |
| EPS | 0.22 | 16.98 | 1.40 | -98.70% | -84.29% |
* Consolidated data